NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the company has been awarded a grant from Israel's prestigious Chief Scientist Office (CSO). The company will receive approximately $870,000 over the remainder of the current fiscal year to fund the continuing development of treatments for ALS and Parkinson’s disease.
